Hereditary angioedema (HAE) is a rare autosomal genetic disease for which there are currently nine FDA-approved drugs. This review summarizes drug treatments for HAE based on four therapeutic pathways: inhibiting the contact system, inhibiting bradykinin binding to B2 receptors, supplying missing C1 inhibitors, and inhibiting plasminogen conversion. The review generalizes the clinical use, pharmacological effects and mechanisms of HAE drugs, and it also discusses possible development directions and targets to enhance understanding of HAE and help researchers.

中文翻译：

---

遗传性血管性水肿医学的总结和未来

遗传性血管性水肿 (HAE) 是一种罕见的常染色体遗传病，目前 FDA 批准了九种治疗药物。本综述总结了基于四种治疗途径的 HAE 药物治疗：抑制接触系统、抑制缓激肽与 B2 受体结合、提供缺失的 C1 抑制剂和抑制纤溶酶原转化。该综述概括了HAE药物的临床应用、药理作用和机制，并讨论了可能的发展方向和目标，以加深对HAE的了解并帮助研究人员。